Drug
Nbi 1065890
Nbi 1065890: highest development phase Phase 2, developed by Neurocrine Biosciences. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Neurocrine Biosciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| NBI-1065890 NCT07365462 | Phase 2 | Tardive Dyskinesia |
Latest
No recent events.
Follow Nbi 1065890 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.